Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Angioedema; Urticaria
  • Focus Registrational; Therapeutic Use
  • Acronyms X-ACT
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 23 Oct 2017 Results of impairment and improvment of angioedema-related quality of life in patients treated with omalizumab published in the Allergy.
    • 24 Mar 2016 Primary endpoint (Chronic urticaria quality of life questionnaire (CU-Q2oL)) has been met, according to results published in the allergy.
    • 24 Mar 2016 Results published in the Allergy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top